Apogee Therapeutics (APGE) to Post Quarterly Earnings on Monday

Key Points

• Apogee Therapeutics is expected to report Q2 2026 results before the market opens Monday, August 10. Analysts project a loss of $1.07 per share and revenue of $10 million; the earnings call is scheduled for August 11 at 9:30 a.m. ET.
• The company narrowly beat the prior-quarter EPS consensus, reporting a loss of $1.06 versus expectations of $1.07. Analysts expect full-year and next-year losses of approximately $4 and $5 per share, respectively.
• APGE shares recently reached a one-year high of $134.46, while the analyst consensus remains “Hold” with a $121.25 price target. Insiders have sold 182,900 shares worth about $21.7 million over the past 90 days.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) is projected to issue its Q2 2026 results before the market opens on Monday, August 10th. Analysts expect Apogee Therapeutics to post earnings of ($1.07) per share and revenue of $10.00 million for the quarter. Investors can check the company's upcoming Q2 2026 earning results page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 9:30 AM ET.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last released its earnings results on Monday, May 11th. The company reported ($1.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.07) by $0.01. On average, analysts expect Apogee Therapeutics to post $-4 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Apogee Therapeutics Price Performance

Shares of Apogee Therapeutics stock opened at $134.09 on Monday. The firm has a market cap of $8.30 billion, a price-to-earnings ratio of -30.97 and a beta of 0.32. The stock's 50-day moving average is $113.95 and its 200-day moving average is $90.07. Apogee Therapeutics has a one year low of $34.34 and a one year high of $134.46.

Insider Transactions at Apogee Therapeutics

In other news, CEO Michael Thomas Henderson sold 20,000 shares of the stock in a transaction that occurred on Wednesday, July 8th. The stock was sold at an average price of $133.63, for a total value of $2,672,600.00. Following the completion of the sale, the chief executive officer owned 995,987 shares of the company's stock, valued at approximately $133,093,742.81. This represents a 1.97% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Carl Dambkowski sold 5,500 shares of the firm's stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $132.74, for a total transaction of $730,070.00. Following the completion of the transaction, the insider directly owned 177,873 shares of the company's stock, valued at $23,610,862.02. This represents a 3.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 182,900 shares of company stock worth $21,711,585. 24.30% of the stock is owned by company insiders.

Institutional Trading of Apogee Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. T. Rowe Price Investment Management Inc. raised its stake in Apogee Therapeutics by 189,522.2% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 2,732,456 shares of the company's stock valued at $206,246,000 after buying an additional 2,731,015 shares during the period. Janus Henderson Group PLC boosted its stake in shares of Apogee Therapeutics by 324.4% during the 4th quarter. Janus Henderson Group PLC now owns 2,062,604 shares of the company's stock worth $155,697,000 after acquiring an additional 1,576,626 shares during the period. Wellington Management Group LLP boosted its stake in shares of Apogee Therapeutics by 24.1% during the 3rd quarter. Wellington Management Group LLP now owns 4,723,701 shares of the company's stock worth $187,673,000 after acquiring an additional 917,991 shares during the period. UBS Group AG increased its holdings in shares of Apogee Therapeutics by 646.1% during the 3rd quarter. UBS Group AG now owns 799,465 shares of the company's stock worth $31,763,000 after acquiring an additional 692,308 shares during the last quarter. Finally, Remedium Capital Partners LLC acquired a new position in shares of Apogee Therapeutics during the 4th quarter worth approximately $44,050,000. Institutional investors and hedge funds own 79.04% of the company's stock.

Wall Street Analyst Weigh In

APGE has been the topic of a number of recent research reports. Guggenheim lowered Apogee Therapeutics from a "buy" rating to a "neutral" rating in a research report on Tuesday, June 23rd. UBS Group downgraded Apogee Therapeutics from a "buy" rating to a "neutral" rating and upped their price target for the stock from $100.00 to $135.11 in a research report on Tuesday, June 23rd. Royal Bank Of Canada raised their price target on shares of Apogee Therapeutics from $82.00 to $97.00 and gave the stock a "sector perform" rating in a research note on Monday, June 8th. Deutsche Bank Aktiengesellschaft downgraded shares of Apogee Therapeutics from a "buy" rating to a "hold" rating and lifted their price objective for the company from $116.00 to $135.00 in a report on Monday, June 22nd. Finally, Craig Hallum set a $135.11 price objective on shares of Apogee Therapeutics and gave the stock a "hold" rating in a research report on Monday, June 22nd. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fifteen have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $121.25.

About Apogee Therapeutics

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company's lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.